Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up

Código QR

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up

Nadezhda P Cvetkova, Kristina Hölldobler, Philipp Prahs, Viola Radeck, Horst Helbig, David Märker Department of Ophthalmology, University of Regensburg, Regensburg, Germany Purpose: Our aim was to evaluate an optical coherence tomography (OCT) and visual acuity (VA)-guided, varia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cvetkova NP, Hölldobler K, Prahs P, Radeck V, Helbig H, Märker D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	AMD neovascular OCT Ranibizumab Retina Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/034123d2f1cb4cb182f09727e4b49dd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014)

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
por: Apsangikar P, et al.
Publicado: (2021)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
por: Russo A, et al.
Publicado: (2018)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
por: Razi F, et al.
Publicado: (2016)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
por: Varsha Pramil, et al.
Publicado: (2021)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Preoperative intravitreal Ranibizumab with panretinal photocoagulation followed by conventional trabeculectomy without drainage device for neovascular glaucoma
por: Xiao-Dong Han, et al.
Publicado: (2021)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Comparing Effectiveness of Three Different Anti-VEGF Treatment Regimens for Neovascular Age-Related Macular Degeneration: Two Years’ Real-World Clinical Outcomes
por: Horner F, et al.
Publicado: (2021)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
por: Sagong M, et al.
Publicado: (2021)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis D, et al.
Publicado: (2017)

Choriocapillaris Vascular Density Changes: Healthy vs. Advanced Exudative Age-Related Macular Degeneration Previously Treated with Multiple Anti-VEGF Intravitreal Injections
por: Maria Cristina Savastano, et al.
Publicado: (2021)

Long-term follow-up of patients with choroidal neovascularization due to angioid streaks
por: Martinez-Serrano MG, et al.
Publicado: (2016)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018)

Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients
por: Jin-Ho Joo, et al.
Publicado: (2021)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
por: S. A. Korotkikh, et al.
Publicado: (2016)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
por: Zhuang Cui, et al.
Publicado: (2021)

Quantifying choriocapillaris hypoperfusion in patients with choroidal neovascularization using swept-source OCT angiography
por: Keiner CM, et al.
Publicado: (2019)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
por: Yan Lu, et al.
Publicado: (2021)

No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration
por: Schroeder M, et al.
Publicado: (2017)

Choroidal neovascularization complicating sclerochoroidal calcifications
por: Maurizio Battaglia Parodi, et al.
Publicado: (2021)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
por: Dirani A, et al.
Publicado: (2018)

Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients
por: Filek R, et al.
Publicado: (2019)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan CS, et al.
Publicado: (2017)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019)

Subclinical Signs of Retinal Involvement in Hereditary Angioedema
por: Paola Triggianese, et al.
Publicado: (2021)

Multimodal imaging and diagnosis of myopic choroidal neovascularization in Caucasians
por: Milani P, et al.
Publicado: (2016)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy B, et al.
Publicado: (2020)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi K, et al.
Publicado: (2018)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis N, et al.
Publicado: (2016)